NCT00486538View on ClinicalTrials.gov

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2012

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

ABT-869

One oral dose daily.

Trial Locations (13)

15232

Site Reference ID/Investigator# 6269, Pittsburgh

19111

Site Reference ID/Investigator# 5249, Philadelphia

Site Reference ID/Investigator# 6278, Philadelphia

20010

Site Reference ID/Investigator# 5243, Washington D.C.

29425

Site Reference ID/Investigator# 7300, Charleston

60637

Site Reference ID/Investigator# 5384, Chicago

95817

Site Reference ID/Investigator# 7193, Sacramento

02114

Site Reference ID/Investigator# 11662, Boston

Site Reference ID/Investigator# 11663, Boston

Site Reference ID/Investigator# 5379, Boston

03756-0001

Site Reference ID/Investigator# 5380, Lebanon

77030-4009

Site Reference ID/Investigator# 6796, Houston

V5Z 4E6

Site Reference ID/Investigator# 6566, Vancouver

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00486538 - Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | Biotech Hunter | Biotech Hunter